,58 Specifically, an ASO-based therapeutic compound, AOC 1001, designed for efficient delivery into muscle cells, has successfully passed phase 1/2 clinical trials, reducing DMPK mRNA, improving splicing profiles, and various functional parameters in DM1 patients.57 This evidence concerns the gene DMPK and myotonic dystrophy type 1.